200 related articles for article (PubMed ID: 23190519)
1. Influence of serum in hemodialysis patients on the expression of intestinal and hepatic transporters for the excretion of pravastatin.
Tsujimoto M; Hatozaki D; Shima D; Yokota H; Furukubo T; Izumi S; Yamakawa T; Minegaki T; Nishiguchi K
Ther Apher Dial; 2012 Dec; 16(6):580-7. PubMed ID: 23190519
[TBL] [Abstract][Full Text] [Related]
2. Effects of Uremic Serum Residue on OATP1B1- and OATP1B3-Mediated Pravastatin Uptake in OATP-Expressing HEK293 Cells and Human Hepatocytes.
Uchiyama H; Tsujimoto M; Kimura A; Yuki E; Saiki T; Yoshida T; Furukubo T; Izumi S; Yamakawa T; Tachiki H; Minegaki T; Nishiguchi K
Ther Apher Dial; 2019 Apr; 23(2):126-132. PubMed ID: 30318712
[TBL] [Abstract][Full Text] [Related]
3. Cooperative inhibitory effects of uremic toxins and other serum components on OATP1B1-mediated transport of SN-38.
Katsube Y; Tsujimoto M; Koide H; Ochiai M; Hojyo A; Ogawa K; Kambara K; Torii N; Shima D; Furukubo T; Izumi S; Yamakawa T; Minegaki T; Nishiguchi K
Cancer Chemother Pharmacol; 2017 Apr; 79(4):783-789. PubMed ID: 28314987
[TBL] [Abstract][Full Text] [Related]
4. Effects of uremic serum and uremic toxins on hepatic uptake of digoxin.
Tsujimoto M; Kinoshita Y; Hirata S; Otagiri M; Ohtani H; Sawada Y
Ther Drug Monit; 2008 Oct; 30(5):576-82. PubMed ID: 18708994
[TBL] [Abstract][Full Text] [Related]
5. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.
Kivistö KT; Niemi M
Pharm Res; 2007 Feb; 24(2):239-47. PubMed ID: 17177112
[TBL] [Abstract][Full Text] [Related]
6. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia.
Lim CF; Bernard BF; de Jong M; Docter R; Krenning EP; Hennemann G
J Clin Endocrinol Metab; 1993 Feb; 76(2):318-24. PubMed ID: 8432774
[TBL] [Abstract][Full Text] [Related]
7. Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney.
Deguchi T; Ohtsuki S; Otagiri M; Takanaga H; Asaba H; Mori S; Terasaki T
Kidney Int; 2002 May; 61(5):1760-8. PubMed ID: 11967025
[TBL] [Abstract][Full Text] [Related]
8. Characterization of uremic toxin transport by organic anion transporters in the kidney.
Deguchi T; Kusuhara H; Takadate A; Endou H; Otagiri M; Sugiyama Y
Kidney Int; 2004 Jan; 65(1):162-74. PubMed ID: 14675047
[TBL] [Abstract][Full Text] [Related]
9. Effects of decreased vitamin D and accumulated uremic toxin on human CYP3A4 activity in patients with end-stage renal disease.
Tsujimoto M; Nagano Y; Hosoda S; Shiraishi A; Miyoshi A; Hiraoka S; Furukubo T; Izumi S; Yamakawa T; Minegaki T; Nishiguchi K
Toxins (Basel); 2013 Aug; 5(8):1475-85. PubMed ID: 23965431
[TBL] [Abstract][Full Text] [Related]
10. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
Maeda K; Ieiri I; Yasuda K; Fujino A; Fujiwara H; Otsubo K; Hirano M; Watanabe T; Kitamura Y; Kusuhara H; Sugiyama Y
Clin Pharmacol Ther; 2006 May; 79(5):427-39. PubMed ID: 16678545
[TBL] [Abstract][Full Text] [Related]
11. Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans.
Fujita K; Sugiura T; Okumura H; Umeda S; Nakamichi N; Watanabe Y; Suzuki H; Sunakawa Y; Shimada K; Kawara K; Sasaki Y; Kato Y
Pharm Res; 2014 Jan; 31(1):204-15. PubMed ID: 23921491
[TBL] [Abstract][Full Text] [Related]
12. Possibility of decrease in CYP1A2 function in patients with end-stage renal disease.
Tsujimoto M; Sugimoto S; Nagatomo M; Furukubo T; Izumi S; Yamakawa T; Minegaki T; Nishiguchi K
Ther Apher Dial; 2014 Apr; 18(2):174-80. PubMed ID: 24119207
[TBL] [Abstract][Full Text] [Related]
13. Effects of renal failure on drug transport and metabolism.
Sun H; Frassetto L; Benet LZ
Pharmacol Ther; 2006 Jan; 109(1-2):1-11. PubMed ID: 16085315
[TBL] [Abstract][Full Text] [Related]
14. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.
Niemi M; Arnold KA; Backman JT; Pasanen MK; Gödtel-Armbrust U; Wojnowski L; Zanger UM; Neuvonen PJ; Eichelbaum M; Kivistö KT; Lang T
Pharmacogenet Genomics; 2006 Nov; 16(11):801-8. PubMed ID: 17047488
[TBL] [Abstract][Full Text] [Related]
15. Effect of uremic serum and uremic toxins on drug metabolism in human microsomes.
Volpe DA; Tobin GA; Tavakkoli F; Dowling TC; Light PD; Parker RJ
Regul Toxicol Pharmacol; 2014 Mar; 68(2):297-303. PubMed ID: 24184159
[TBL] [Abstract][Full Text] [Related]
16. Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport.
Kindla J; Müller F; Mieth M; Fromm MF; König J
Drug Metab Dispos; 2011 Jun; 39(6):1047-53. PubMed ID: 21389119
[TBL] [Abstract][Full Text] [Related]
17. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.
Yamashiro W; Maeda K; Hirouchi M; Adachi Y; Hu Z; Sugiyama Y
Drug Metab Dispos; 2006 Jul; 34(7):1247-54. PubMed ID: 16624871
[TBL] [Abstract][Full Text] [Related]
18. The disposition of pravastatin in a rat model of streptozotocin-induced diabetes and organic anion transporting polypeptide 2 and multidrug resistance-associated protein 2 expression in the liver.
Hasegawa Y; Kishimoto S; Shibatani N; Inotsume N; Takeuchi Y; Fukushima S
Biol Pharm Bull; 2010; 33(1):153-6. PubMed ID: 20045956
[TBL] [Abstract][Full Text] [Related]
19. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin.
Sun H; Huang Y; Frassetto L; Benet LZ
Drug Metab Dispos; 2004 Nov; 32(11):1239-46. PubMed ID: 15286055
[TBL] [Abstract][Full Text] [Related]
20. Renal disposition of a furan dicarboxylic acid and other uremic toxins in the rat.
Tsutsumi Y; Deguchi T; Takano M; Takadate A; Lindup WE; Otagiri M
J Pharmacol Exp Ther; 2002 Nov; 303(2):880-7. PubMed ID: 12388676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
